• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Catalent Biologics Completes Madison Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Syngene

    Baxter BioPharma Solutions

    Emergent BioSolutions

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Alcami

    Aphena Pharma Solutions

    Adare Pharma Solutions

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Ovid and UConn Enter Strategic Research Collaboration

    Aim to accelerate the development of next-gen genetic therapy for Angelman Syndrome.

    Related CONTENT
    • Charles River Acquires Retrogenix
    • Rentschler Biopharma Names Martin Kessler as New CEO in U.S.
    • Cold-Chain Handling Is Not Just a COVID Vaccine Challenge
    • Advanced Analytics Advancing Development of Genetic Vaccines
    • BioCentriq, Kytopen Enter Cell Therapy Alliance
    Contract Pharma Staff07.23.20
    Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, and the University of Connecticut School of Medicine, have announced a research collaboration and license agreement to accelerate the development of a next-generation short hairpin RNA (shRNA)-based therapeutic for Angelman syndrome and potentially other indications.
     
    The most common cause of Angelman syndrome is the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), which plays a critical role in nerve cell communication, resulting in impaired tonic inhibition. Ovid and UConn believe that an shRNA-based therapeutic may address this underlying genetic cause of Angelman syndrome by reducing the expression of UBE3A-antisense, potentially restoring the function of UBE3A. This genetic approach may be used in combination with OV101 (gaboxadol), Ovid’s novel, small-molecule delta (δ)-selective GABAA receptor agonist, to restore tonic inhibition and address the underlying symptomology of individuals with Angelman syndrome. OV101 is currently being evaluated in the pivotal Phase 3 Neptune trial in Angelman syndrome, with topline results expected in the fourth quarter of 2020.
     
    Under the terms of the research collaboration, Ovid will work closely with UConn’s Stormy J. Chamberlain, Ph.D., and gain exclusive access to identified genetic sequences for a potential shRNA-based therapeutic. Ovid plans to validate select sequences and leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance an shRNA-based therapeutic into clinical studies. Chamberlain is recognized in the field of Angelman syndrome and UBE3A research and currently serves as the John and Donna Krenicki associate professor of genomics and personalized healthcare in UConn’s Genetics and Genome Sciences Department. In addition, Chamberlain chairs the Angelman Syndrome Foundation (ASF) Scientific Advisory Committee and is a member of the Dup15q Alliance Scientific Advisory Board. Ovid will also work closely with UConn’s Noelle Germain, Ph.D., assistant professor of genetics and genome sciences on these efforts.
     
    “Ovid is deeply committed to the Angelman syndrome community. We have made great progress and are excited to see the topline data from our Phase 3 NEPTUNE trial with OV101 expected in Q4 2020,” said Amit Rakhit, M.D., MBA, president and chief medical officer of Ovid Therapeutics. “We believe OV101 has the potential to serve as a core therapy for this disorder and are now focused on building a comprehensive and strategic Angelman syndrome longer term pipeline. If successful, OV101 may be used in combination with genetic approaches in the future to address the needs of Angelman syndrome.”
     
    “Our lab shares in Ovid’s demonstrated commitment to advance innovative therapeutic options for Angelman syndrome,” stated Chamberlain. “An shRNA therapeutic can target the genetic cause of Angelman syndrome at its source and may offer potential advantages to other next-generation approaches, including antisense oligonucleotide therapy, via a lower rate of degradation and turnover and plasmid delivery allowing for a less-frequent dosing profile. Ovid is uniquely positioned to accelerate an shRNA therapeutic through late preclinical and clinical development, and our lab looks forward to working with the team at Ovid towards our common objective of impacting the lives of individuals living with Angelman syndrome and their families.”
    Related Searches
    • Drug Development
    Suggested For You
    Charles River Acquires Retrogenix Charles River Acquires Retrogenix
    Rentschler Biopharma Names Martin Kessler as New CEO in U.S. Rentschler Biopharma Names Martin Kessler as New CEO in U.S.
    Cold-Chain Handling Is Not Just a COVID Vaccine Challenge Cold-Chain Handling Is Not Just a COVID Vaccine Challenge
    Advanced Analytics Advancing Development of Genetic Vaccines Advanced Analytics Advancing Development of Genetic Vaccines
    BioCentriq, Kytopen Enter Cell Therapy Alliance BioCentriq, Kytopen Enter Cell Therapy Alliance
    BioCentriq and Kytopen Enter Cell Therapy Partnership BioCentriq and Kytopen Enter Cell Therapy Partnership
    LabConnect Expands Johnson City Facility LabConnect Expands Johnson City Facility
    Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy
    High Purity New England & Univercells Technologies Unveil Bioprocessing Solutions High Purity New England & Univercells Technologies Unveil Bioprocessing Solutions
    Cytovance Biologics Offers Licensing for Plasmid DNA Manufacturing Cytovance Biologics Offers Licensing for Plasmid DNA Manufacturing
    AGC Biologics Expands Cell and Gene Facility in Italy AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Reshaping the Pharmaceutical Supply Chain Reshaping the Pharmaceutical Supply Chain
    Spark Therapeutics Appoints CTO Spark Therapeutics Appoints CTO

    Related Breaking News

    • Breaking News | Clinical Trials | Drug Development | Trials & Filings
      FDA Accepts Airway Therapeutics’ IND for COVID Treatment

      FDA Accepts Airway Therapeutics’ IND for COVID Treatment

      To initiate a Phase 1b trial to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.
      Kristin Brooks 04.12.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Sanofi Acquires Tidal Therapeutics

      Sanofi Acquires Tidal Therapeutics

      Gains novel mRNA-based technology with research capabilities in immuno-oncology and inflammatory diseases, with potential in other disease areas.
      Kristin Brooks 04.12.21

    • Analytical Services | Breaking News | Clinical Trial Materials | Drug Development | Industry News
      Ascendia Pharmaceuticals Poised for Expansion

      Ascendia Pharmaceuticals Poised for Expansion

      CDMO secures growth equity investment from Signet Healthcare Partners.
      Tim Wright, Editor, Contract Pharma 04.09.21


    • Breaking News | Collaborations & Alliances | Drug Delivery | Drug Development | Industry News
      Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

      Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

      Work together to develop and commercialize CHI’s novel dry-powder inhaler product.
      Charles Sternberg, Assistant Editor 04.07.21

    • Breaking News | Clinical Trials | Drug Development | Industry News
      Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

      Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

      To support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.
      Kristin Brooks 04.06.21

    • Breaking News | Clinical Trials | CRO News | Drug Development
      Moleculin Selects IQVIA Biotech to Advance COVID Treatment

      Moleculin Selects IQVIA Biotech to Advance COVID Treatment

      IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
      Kristin Brooks 04.06.21


    • Breaking News | Drug Development
      Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

      Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

      Expands its oncology leadership capabilities in the U.S.
      Charles Sternberg, Assistant Editor 04.01.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined company brings complementary Ribosomal RNA-targeted genetic therapy platforms together.
      Kristin Brooks 04.01.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.
      Kristin Brooks 03.30.21


    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Facilities | Industry News
      Chime Biologics Expands CDMO Capabilities

      Chime Biologics Expands CDMO Capabilities

      Completes $190 million financing round to accelerate capacity expansion.
      Tim Wright, Editor, Contract Pharma 03.29.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development | Industry News
      CyanVac and Exothera Enter COVID-19 Vaccine Partnership

      CyanVac and Exothera Enter COVID-19 Vaccine Partnership

      CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.
      Tim Wright, Editor, Contract Pharma 03.25.21

    • Breaking News | Drug Development | Facilities | Industry News | Parenterals
      Eisai Begins Construction of New Injection/Research Building

      Eisai Begins Construction of New Injection/Research Building

      To accommodate expanded drug discovery targets and new modalities such as antibodies, ADCs, and nucleic acid drugs.
      Kristin Brooks 03.22.21


    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Evotec, Takeda Enter Multi-RNA Target Alliance

      Evotec, Takeda Enter Multi-RNA Target Alliance

      To discover and develop small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
      Kristin Brooks 03.22.21

    • Breaking News | Clinical Trials | Drug Development | Trials & Filings
      Gilead, Novo Nordisk Expand NASH Alliance

      Gilead, Novo Nordisk Expand NASH Alliance

      Phase II trial to investigate Novo’s semaglutide and a combination of Gilead’s cilofexor and firsocostat, alone and in combination in cirrhosis due to NASH.
      Kristin Brooks 03.18.21

    • Breaking News | Clinical Trials | Drug Development | Trials & Filings
      Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy

      Cytocom Gets FDA Clearance for Phase II Trial of COVID Immune Therapy

      Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2.
      Kristin Brooks 03.16.21

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Catalent Biologics Completes Madison Expansion
    • ANI Acquires Branded Products Portfolio From Sandoz
    Breaking News
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    • Catalent Biologics Completes Madison Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study
    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    KD Pharma Acquires Rohner AG Manufacturing Assets
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    HMG Paints Reports Positive Feedback on Contract Matt Emulsion
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BioSig Launches Software Update for PURE EP Electrophysiology Platform
    Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    Vicarious Surgical Appoints CFO and Chief Legal Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Executive Moves: Novavax
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    BASF Increases Price of Kaolin
    Kao Launches Online Beauty Store in Europe
    Neutrogena Takes Action on Skin Health Disparities
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Edale appoints agent in Poland
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Aries Face Masks Meet ASTM Standards
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Biogennix Rolls Out Agilon Strip Bone Graft
    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login